The FDA has classified Vitruvias Therapeutics' recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units.
FDA upgrades Vitruvias Therapeutics recall: Superpotent thyroid tablets could trigger heart problems; who is at risk?
Published ·
Keep reading
Related stories
